EUCTR2010-022895-30-NL进行中（未招募）不适用
A 12-week, multicentre, randomised, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Symbicort® 200/6 (budesonide 200 µg plus formoterol 6 µg/actuation), 2 inhalations b.i.d., on parameters of small airway function in patients with Chronic Obstructive Pulmonary Disease.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients aged = 40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure or when applicable written informed consent obtained by legal representative.
- •2.Outpatients with a clinical diagnosis of moderate to severe COPD and including:
- •a)Smoking history of at least 10 pack years defined as [(number of cigarettes smoked per day) x (number of years of smoking)] / 20, both current and ex-smokers are eligible.
- •b)Regular use of bronchodilators (e.g. ß2-agonist, anticholinergics) in the 2 months before visit 1.
- •c)Post-bronchodilator FEV1 < 65% of the predicted normal value at visit 1.
- •d)Post-bronchodilator FEV1/FVC < 0.7 at visit 1.
- •e)An increase in FEV1 < 15% and < 200 mL from baseline following administration of 400 µg of salbutamol at visit 1.
- •f)Plethysmographic Functional Residual Capacity (FRC) > 120% of the predicted normal value (at visit 1 and visit 2).
- •g)A Baseline Dyspnoea Index (BDI) focal score < or = 10 (at visit 1 and at visit 2).
- •3.A cooperative attitude and ability to be trained to the proper use of pMDI and DPI (Turbohaler®, inspiratory flow-driven, multidose powder inhaler) inhalers.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1.Diagnosis of asthma or other clinically or functionally relevant respiratory disorders (other than COPD) which may interfere with data interpretation according to the investigator’s opinion.
- •2.Pregnant or lactating women. Females of childbearing potential without an efficient contraception UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or are using one or more of the following acceptable methods of contraception:
- •a) surgical sterilization (e.g. bilateral tubal ligation, hysterectomy);
- •b) hormonal contraception (implantable, patch, oral, injectable);
- •c) barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/cream/suppository.
- •d) Continuous abstinence (e.g. nuns).
- •Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation.
- •3.Clinically unstable concurrent disease: e.g. hyperthyroidism, diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; cardiovascular disease (e.g. coronary artery disease, hypertension, heart failure); gastrointestinal disease (e.g. active peptic ulcer); neurological disease; haematological disease; autoimmune disorders, or other which may impact the evaluation of the results of the study according to investigator’s judgement.
- •4.Patient with narrow-angle glaucoma.
- •5.Clinically significant laboratory and ECG abnormalities indicating a significant or unstable concomitant disease which may impact the evaluation of the results of the study and the safety of the patient according to investigator’s judgement.
- •6.Patients with COPD exacerbation and/or symptomatic infection of the airways requiring antibiotic therapy (at least 5 days) in the 2 months prior to screening and during the study period. COPD exacerbation will be defined according to the following: A sustained worsening of the patient’s condition (dyspnoea, cough and/or sputum production/purulence), from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD that includes prescriptions of systemic corticosteroids (at least 3 days) and/or antibiotics (at least 5 days), or need for a visit to an emergency department or hospitalization”.
- •7.Patients requiring long term (> 12 hours daily) oxygen therapy for chronic hypoxemia.
- •8.Patients treated with depot corticosteroids in the 2 months preceding the visit 1 and during the run-in period.
- •9.Patients with known allergy, sensitivity or intolerance to sympathomimetic drugs or inhaled corticosteroids or to any of the excipients contained in the study drugs.
- •10.Patients who have evidence of alcohol or drug abuse, not compliant with the study protocol or not compliant with the study treatments according to investigator’s judgement.
- •11.Major surgery in the previous 3 months and during the trial which may affect patient’s compliance in study procedures (e.g. plethysmography).
- •12.Participation in another clinical trial with an investigational drug in the 2 months preceding visit 1.
- •13.Patients requiring chronic mechanical ventilation for COPD.
研究者
相似试验
已完成
3 期
A 12-week, multicentre, randomised, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Symbicort® 200/6 (budesonide 200 µg plus formoterol 6 µg/actuation), 2 inhalations b.i.d., on parameters of small airway function in patients with Chronic Obstructive Pulmonary Disease.Lung of smoker10037454chronic bronchitisNL-OMON38416Chiesi Farmaceutici170
进行中（未招募）
1 期
A study evaluating the safety and efficacy of safinamide for patients with Multiple System AtrophyParkinsonian variant of Multiple System AtrophyMedDRA version: 20.0Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-004145-16-ESZambon SpA49
进行中（未招募）
1 期
A study evaluating the safety and efficacy of safinamide for patients with Multiple System AtrophyParkinsonian variant of Multiple System AtrophyMedDRA version: 21.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-004145-16-ITZAMBON SPA48
进行中（未招募）
不适用
A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 beta monoclonal antibody) with three different dose regimens in patients with active rheumatoid arthritis despite stable treatment with methotrexateActive Rheumatoid ArthritisEUCTR2006-001550-27-DEovartis Pharma AG293
进行中（未招募）
1 期
Study of efficacy and safety of CSJ117 in patients with severe uncontrolled asthma.AsthmaEUCTR2019-004905-29-ITOVARTIS PHARMA AG335